Shanghai Junshi Announces Chinese Adalimumab Approval

Partnered With Mabwell On Biosimilar Rival To Humira

 
• By Dave Wallace

Shanghai Junshi and Mabwell have received approval from China’s NMPA for their co-developed adalimumab biosimilar rival to Humira.

China Flag Thumbs Up
Shanghai Junshi and Mabwell have received approval for adalimumab • Source: Micha Klootwijk / Alamy Stock Photo

More from Biosimilars

More from Products